Top Markets
#1 Nesa Nesa +720.45%
#2 EXOD EXOD +22.78%
#3 MetaDAO MetaDAO +14.20%
#4 Venom Venom +10.59%
#5 Pons Pons +9.49%
#6 PondCoin PondCoin +8.69%
#7 Status Status +8.08%
#8 Wrapped NXM Wrapped NXM +8.03%
#9 Prom Prom +7.99%
#10 Ontology Gas Ontology Gas +7.17%
Coin of the day
Nesa Nesa
設定
言語
日本
通貨
USD
テーマ
Photocure ASA Photocure ASA

Photocure ASA

PHO
株式のランク #19788
Photocure ASA is a specialized pharmaceutical enterprise focused on the... Photocure ASA is a specialized pharmaceutical enterprise focused on the development, manufacturing, commercialization, and distribution of medicinal products. Its operational footprint extends across multiple European nations, including the Nordic region, Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, in addition to the United States. The company's primary offering, Hexvix/Cysview, aids in the identification and ongoing management of bladder cancer. Moreover, Photocure is actively progressing Cevira, a therapeutic agent in development targeting human papilloma virus (HPV) infections and pre-cancerous lesions of the cervix. The firm distributes its products to pharmaceutical wholesalers, pharmacies, and healthcare institutions through collaborative licensing arrangements. Founded in 1993, Photocure ASA maintains its corporate headquarters in Oslo, Norway.
株価
$5.66
最終同期: 2026-08-25
時価総額
$150.59M
変化（1日）
0.00%
変化（1年）
-7.22%
国
NO
取引 Photocure ASA (PHO)

カテゴリー

Healthcare
Photocure ASA（PHO）のP/B比率
2026 時点のP/B比率 TTM: 0
Photocure ASA の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0 です。2026 年末時点でのP/B比率は 0 でした。
Photocure ASA の P/B 比率の履歴（2026 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH